Zosano Pharma Corp (NASDAQ:ZSAN) was down 5.2% during mid-day trading on Wednesday following a weaker than expected earnings announcement. The company traded as low as $2.88 and last traded at $3.12. Approximately 657,614 shares changed hands during mid-day trading, a decline of 61% from the average daily volume of 1,685,043 shares. The stock had previously closed at $3.29.
The biotechnology company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.78) by ($0.01).
ZSAN has been the subject of a number of research analyst reports. ValuEngine upgraded Zosano Pharma from a “hold” rating to a “buy” rating in a research report on Friday, February 22nd. Cantor Fitzgerald initiated coverage on Zosano Pharma in a research report on Monday, April 22nd. They set an “overweight” rating and a $3.66 price target for the company. Finally, Maxim Group initiated coverage on Zosano Pharma in a research report on Wednesday, April 17th. They set a “buy” rating and a $8.00 price target for the company.
In other news, CEO John Peter Walker bought 100,000 shares of the company’s stock in a transaction that occurred on Thursday, April 11th. The stock was bought at an average price of $3.50 per share, for a total transaction of $350,000.00. Following the transaction, the chief executive officer now directly owns 280,228 shares of the company’s stock, valued at approximately $980,798. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.71% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the stock. Aisling Capital Management LP bought a new stake in Zosano Pharma in the 4th quarter worth approximately $3,392,000. BlackRock Inc. lifted its position in Zosano Pharma by 1,031.7% in the 1st quarter. BlackRock Inc. now owns 311,771 shares of the biotechnology company’s stock worth $1,487,000 after buying an additional 284,222 shares during the last quarter. Telemetry Investments L.L.C. lifted its position in Zosano Pharma by 37.8% in the 4th quarter. Telemetry Investments L.L.C. now owns 219,040 shares of the biotechnology company’s stock worth $464,000 after buying an additional 60,069 shares during the last quarter. MYDA Advisors LLC bought a new stake in Zosano Pharma in the 1st quarter worth approximately $343,000. Finally, Dimensional Fund Advisors LP bought a new stake in Zosano Pharma in the 3rd quarter worth approximately $121,000. Institutional investors own 29.57% of the company’s stock.
The stock has a market capitalization of $55.30 million, a price-to-earnings ratio of -0.83 and a beta of 2.62.
WARNING: “Zosano Pharma (ZSAN) Stock Price Down 5.2% Following Weak Earnings” was published by Modern Readers and is owned by of Modern Readers. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.modernreaders.com/news/2019/05/15/zosano-pharma-zsan-stock-price-down-5-2-following-weak-earnings.html.
Zosano Pharma Company Profile (NASDAQ:ZSAN)
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine.
See Also: How a Back-End Load Mutual Fund Works
Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.